Business Context and Reporting Period
This Form 8-K Current Report was filed by Vanda Pharmaceuticals Inc. on May 13, 2020. The filing addresses a specific corporate event regarding regulatory progress for the company's product, HETLIOZ, rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory milestone and does not contain financial statement data.
Material Changes
The material event reported is an agreement reached with the U.S. Food and Drug Administration (FDA) on May 13, 2020. This agreement concerns:
- The resubmission of the supplemental New Drug Application (NDA) for the solid capsule formulation of HETLIOZ for the treatment of adults with Smith-Magenis Syndrome (SMS).
- The New Drug Application for the liquid formulation of HETLIOZ for the treatment of children with SMS.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the FDA agreement. The filing incorporates a press release (Exhibit 99.1) for full details. No specific financial guidance, outlook, or discussion of risks and contingencies is provided within the text of this 8-K form.
Investor Verification Checklist
- Verify the full text of the press release filed as Exhibit 99.1 for specific details on the FDA agreement terms.
- Confirm the status of the resubmitted NDAs for both adult (solid capsule) and pediatric (liquid) HETLIOZ formulations.
- Review subsequent filings for any updates on the FDA review timeline or potential approval dates.